Correlation Between Estrella Immunopharma and Scopus Biopharma
Can any of the company-specific risk be diversified away by investing in both Estrella Immunopharma and Scopus Biopharma at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Estrella Immunopharma and Scopus Biopharma into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Estrella Immunopharma and Scopus Biopharma, you can compare the effects of market volatilities on Estrella Immunopharma and Scopus Biopharma and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Estrella Immunopharma with a short position of Scopus Biopharma. Check out your portfolio center. Please also check ongoing floating volatility patterns of Estrella Immunopharma and Scopus Biopharma.
Diversification Opportunities for Estrella Immunopharma and Scopus Biopharma
-0.56 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Estrella and Scopus is -0.56. Overlapping area represents the amount of risk that can be diversified away by holding Estrella Immunopharma and Scopus Biopharma in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Scopus Biopharma and Estrella Immunopharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Estrella Immunopharma are associated (or correlated) with Scopus Biopharma. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Scopus Biopharma has no effect on the direction of Estrella Immunopharma i.e., Estrella Immunopharma and Scopus Biopharma go up and down completely randomly.
Pair Corralation between Estrella Immunopharma and Scopus Biopharma
If you would invest 10.00 in Estrella Immunopharma on August 31, 2024 and sell it today you would lose (0.90) from holding Estrella Immunopharma or give up 9.0% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Very Weak |
Accuracy | 4.76% |
Values | Daily Returns |
Estrella Immunopharma vs. Scopus Biopharma
Performance |
Timeline |
Estrella Immunopharma |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
OK
Scopus Biopharma |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Estrella Immunopharma and Scopus Biopharma Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Estrella Immunopharma and Scopus Biopharma
The main advantage of trading using opposite Estrella Immunopharma and Scopus Biopharma positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Estrella Immunopharma position performs unexpectedly, Scopus Biopharma can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Scopus Biopharma will offset losses from the drop in Scopus Biopharma's long position.Estrella Immunopharma vs. Cue Biopharma | Estrella Immunopharma vs. Tff Pharmaceuticals | Estrella Immunopharma vs. Eliem Therapeutics | Estrella Immunopharma vs. Inhibrx |
Scopus Biopharma vs. Scpharmaceuticals | Scopus Biopharma vs. DiaMedica Therapeutics | Scopus Biopharma vs. Monopar Therapeutics | Scopus Biopharma vs. Pasithea Therapeutics Corp |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Other Complementary Tools
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |